GlassScriptPhysician profile
Cameron K Rokhsar
NPI 1801862271
$13,316.26
in general payments reported to CMS, 2019-2025
24 companies · $831 in 2025
The $831 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,479 · 2020: $385 · 2021: $463 · 2022: $1,596 · 2023: $1,200 · 2024: $362 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.44 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,667.79 | 2019-2022 | |
| Dermira, INC. | $2,283.33 | 2019-2021 | |
| Abbvie INC. | $1,693.64 | 2021-2025 | Botox |
| Merz North America, INC. | $1,033.58 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $602.62 | 2019-2025 | |
| Dermavant Sciences, INC. | $368.68 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $350.86 | 2019-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $315.85 | 2021-2025 | Libtayo |
| Genzyme Corporation | $221.75 | 2021-2025 | |
| Amgen INC. | $133.78 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $98.24 | 2019-2023 | |
| Celgene Corporation | $89.34 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $78.51 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Incyte Corporation | $65.68 | 2022-2024 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $47.11 | 2023-2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $37.03 | 2020 | |
| Journey Medical Corporation | $33.24 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $29.36 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.03 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $18.79 | 2022 | |
| Strata Skin Sciences, INC. | $17.68 | 2025 | Xtrac |
| Smith+Nephew, INC. | $16.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Rokhsar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.